Signaling inhibition with radiation in colorectal cancer: Clinical trials

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 6, 2003, Pages 56-67

  McKenna, W Gillies ^a   Muschel, Ruth J ^b   Gupta, Anjali ^b   Hahn, Stephen ^b   Bernhard, Eric J ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN;

CANCER CELL; CANCER GROWTH; CANCER RADIOTHERAPY; COLORECTAL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR RESISTANCE;

ALKYL AND ARYL TRANSFERASES; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DIMETHYLALLYLTRANSTRANSFERASE; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEINS;

EID: 0037838498     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00126-X     Document Type: Review

References (127)

1. FitzGerald TJ, Daugherty C, Kase K, et al: Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Implications for increased therapeutic ratio of low dose rate irradiation. Am J Clin Oncol 8:517-522, 1985
2. Sklar MD: The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239:645-647, 1988
3. Ling CC, Endlich B: Radioresistance induced by oncogenic transformation. Radiat Res 120:267-279, 1989
4. McKenna WG, Weiss MC, Bakanauskas VJ, et al: The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18:849-859, 1990
5. FitzGerald TJ, Henault S, Sakakeeny M, et al: Expression of transfected recombinant oncogenes increases radiation resistance of clonal hematopoietic and fibroblast cell lines selectively at clinical low dose rate. Radiat Res 122:44-52, 1990
6. Suzuki K, Watanabe M, Miyoshi J: Differences in effects of oncogenes on resistance of gamma rays, ultraviolet light, and heat shock. Radiat Res 129:157-162, 1992
7. Miller AC, Kariko K, Myers CE, et al: Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 53:302-307, 1993
8. Ong A, Li WX, Ling CC: Low-dose-rate irradiation of rat embryo cells containing the Ha-ras oncogene. Radiat Res 134: 251-255, 1993
9. Pirollo KF, Tong YA, Villegas Z, et al: Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype. Radiat Res 135:234-243, 1993
10. McKenna WG, Weiss MC, Endlich B, et al: Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 50:97-102, 1990
11. Su LN, Little JB: Prolonged cell cycle delay in radioresistant human cell lines transfected with activated ras oncogene and/or simian virus 40 T-antigen. Radiat Res 133:73-79, 1993
12. Samid D, Miller AC, Rimoldi D, et al: Increased radiation resistance in transformed and nontransformed cells with elevated ras proto-oncogene expression. Radiat Res 126:244-250, 1991
13. McKenna WG, Iliakis G, Weiss MC, et al: Increased G2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc. Radiat Res 125:283-287, 1991
14. McKenna WG, Bernhard EJ, Markiewicz DA, et al: Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay. Oncogene 12:237-245, 1996
15. Bernhard EJ, Stanbridge EJ, Gupta S, et al: Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 60:6597-6600, 2000
16. Santucci MA, Anklesaria P, Anderson SM, et al: The v-src oncogene may not be responsible for the increased radioresistance of hematopoietic progenitor cells expressing v-src. Radiat Res 129:297-303, 1992
17. Daaka Y, Wickstrom E: Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res 5:267-275, 1990
18. Gray GD, Hernandez OM, Hebel D, et al: Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res 53:577-580, 1993
19. Kashani-Sabet M, Funato T, Florenes VA, et al: Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 54:900-902, 1994
20. Sorrentino R, Porcellini A, Spalletti-Cernia D, et al: Inhibition of MAPK activity, cell proliferation and anchorage-independent growth by N-Ras antisense in an N-ras-transformed human cell line. Antisense Nucleic Acid Drug Dev 11:349-358, 2001
21. Cunningham CC, Holmlund JT, Geary RS, et al: A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92:1265-1271, 2001
22. Nakano M, Aoki K, Matsumoto N, et al: Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. Mol Ther 3:491-499, 2001
23. Tsuchida T, Kijima H, Hori S, et al: Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther 7:373-383, 2000
24. Pirollo KF, Hao Z, Rait A, et al: Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Comm 230:196-201, 1997
25. Russell JS, Lang FF, Huet T, et al: Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. Cancer Res 59:5239-5244, 1999
26. Russell JS, Raju U, Gumin GJ, et al: Inhibition of radiation-induced nuclear factor-kappaB activation by an anti- Ras single-chain antibody fragment: Lack of involvement in radiosensitization. Cancer Res 62:2318-2326, 2002
27. Glomset JA, Farnsworth CC: Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 10:181-205, 1994
28. Gelb MH: Protein prenylation, et cetera: Signal transduction in two dimensions [comment]. Science 275:1750-1751, 1997
29. Bernhard EJ, McKenna WG, Muschel RJ: Radiosensitivity and the cell cycle. Cancer J Sci Am 5:194-204, 1999
30. Sebti S, Hamilton A: Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol Ther 74: 103-114, 1997
31. Waddick KG, Uckun FM: Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. Biochem Pharmacol 56:1411-1426, 1998
32. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459-14464, 1997
33. Sun J, Qian Y, Hamilton AD, et al: Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473, 1998
34. Bernhard EJ, McKenna WG, Hamilton AD, et al: Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 58:1754-1761, 1998
35. Lerner EC, Zhang TT, Knowles DB, et al: Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15:1283-1288, 1997
36. Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesyl/protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55:5302-5309, 1995
37. Servais P, Gulbis B, Fokan D, et al: Effects of the farnesyltransferase inhibitor UCF-1C/ manumycin on growth and p21-ras post-translational processing in NIH3T3 cells. Int J Cancer 76:601-608, 1998
38. Mangues R, Corral T, Kohl NE, et al: Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 58:1253-1259, 1998
39. Du W, Lebowitz PF, Prendergast GC: Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 19:1831-1840, 1999
40. End DW, Smets G, Todd AV, et al: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131-137, 2001
41. Kohl NE, Wilson FR, Mosser SD, et al: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A 91:9141-9145, 1994
42. Sun J, Qian Y, Hamilton AD, et al: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55:4243-4247, 1995
43. Kohl NE, Omer CA, Conner MW, et al: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med 1:792-797, 1995
44. Sun J, Blaskovich MA, Knowles D, et al: Antitumor efficacy of a novel class of non-thiol- containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 59:4919-4926, 1999
45. Lantry LE, Zhang Z, Yao R, et al: Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 21:113-116, 2000
46. Liu A, Du W, Liu JP, et al: RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 20:6105-6113, 2000
47. Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15:6613-6622, 1995
48. Lebowitz PF, Casey PJ, Prendergast GC, et al: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272:15591-15594, 1997
49. Du W, Prendergast GC: Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 59:5492-5496, 1999
50. Liu A, Prendergast GC: Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. FEBS Lett 481:205-208, 2000
51. Miquel K, Pradines A, Sun J, et al: GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 57:1846-1850, 1997
52. Ashar HR, James L, Gray K, et al: The farnesyl transferase inhibitor SCH 66336 induces a G(2) -> M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res 262: 17-27, 2001
53. Hahn SM, Bernhard EJ, Regine W, et al: A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8:1065-1072, 2002
54. Peters DG, Hoover RR, Gerlach MJ, et al: Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97:1404-1412, 2001
55. Song SY, Meszoely IM, Coffey RJ, et al: K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia 2:261-272, 2000
56. Crespo NC, Ohkanda J, Yen TJ, et al: The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276:16161-16167, 2001
57. Feldkamp MM, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18:7514-7526, 1999
58. Barrington RE, Subler MA, Rands E, et al: A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18:85-92, 1998
59. Vogt A, Sun J, Qian Y, et al: The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 272:27224-27229, 1997
60. Vogt A, Qian Y, McGuire TF, et al: Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 13:1991-1999, 1996
61. Bernhard EJ, Kao G, Cox AD, et al: The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 56:1727-1730, 1996
62. Miyaguchi M, Olofsson J, Hellquist HB: Expression of epidermal growth factor receptor in glotic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol 16:466-469, 1991
63. Zhu A, Shaeffer J, Leslie S, et al: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 34:809-815, 1996
64. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000
65. Harari PM, Huang SM: Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49:427-433, 2001
66. Lammering G, Valerie K, Lin PS, et al: Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res 7:682-690, 2001
67. Santini J, Formento JL, Francoual M, et al: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13:132-139, 1991
68. Weichselbaum RR, Dunphy EJ, Beckett MA, et al: Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck 11:437-442, 1989
69. Gupta AK, McKenna WG, Weber CN, et al: Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin Cancer Res 8:885-892, 2002
70. Cohen-Jonathan E, Toulas C, Ader I, et al: The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS. Radiat Res 152:404-411, 1999
71. Gupta AK, Bakanauskas VJ, Cerniglia GJ, et al: The Ras radiation resistance pathway. Cancer Res 61:4278-4282, 2001
72. Kasid U, Pirollo K, Dritschilo A, et al: Oncogenic basis of radiation resistance. Adv Cancer Res 61:195-233, 1993
73. Hagan M, Wang L, Hanley JR, et al: Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 153:371-383, 2000
74. Cartee L, Vrana JA, Wang Z, et al: Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway. Int J Oncol 16:413-422, 2000
75. Gupta AK, Bakanauskas VJ, McKenna WG, et al: Ras regulation of radioresistance in cell culture. Methods Enzymol 333:284-290, 2001
76. Cohen-Jonathan E, Muschel RJ, McKenna WG, et al: Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 154:125-132, 2000
77. End D, Skrzat S, Devine A: R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): Biochemical and cellular effects in H-ras and K-ras dominant systems. Proc Am Assoc Cancer Res 39:270, 1998 (abstr)
78. Zujewski J, Horak ID, Bol CJ, et al: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18:927-941, 2000
79. Punt CJ, van Maanen L, Bol CJ, et al: Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 12:193-197, 2001
80. Karp JE, Lancet JE, Kaufmann SH, et al: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial. Blood 97:3361-3369, 2001
81. Britten CD, Rowinsky E, Yao S-L, et al: The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers. Proc Am Soc Clin Oncol 18:155a, 1999 (abstr 597)
82. Britten CD, Rowinsky EK, Soignet S, et al: A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 7:3894-3903, 2001
83. Langer CJ, Curran WJ, Keller SM, et al: Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Am 2:99, 1996
84. Dillman RO: Concurrent chemoradiation in unresectable stage III non-small cell lung cancer: Too much pain for no gain. Cancer J Sci Am 2:76, 1996
85. Rak J, Mitsuhashi Y, Bayko L, et al: Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575-4580, 1995
86. Senger DR, Van de Water L, Brown LF, et al: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metast Rev 12:303-324, 1993
87. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995
88. Kolch W, Martiny-Baron G, Kieser A, et al: Regulation of the expression of the VEGF/VPS and its receptors: Role in tumor angiogenesis. Breast Cancer Res Treat 36:139-155, 1995
89. Sobel AT, Branellec AI, Blanc CJ, et al: Physicochemical characterization of a vascular permeability factor produced by con A-stimulated human lymphocytes. J Immunol. 119: 1230-1234, 1977
90. Kerbel RS, Viloria-Petit A, Okada F, et al: Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4:286-295, 1998
91. Larcher F, Robles AI, Duran H, et al: Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56:5391-5396, 1996
92. Feleszko W, Balkowiec EZ, Sieberth E, et al: Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81:560-567, 1999
93. Milanini-Mongiat J, Pouyssegur J, Pages G: Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases. Their implication in vascular endothelial growth factor gene transcription. J Biol Chem 277: 20631-20639, 2002
94. Mazure NM, Chen EY, Laderoute KR, et al: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras- transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90:3322-3331, 1997
95. Blancher C, Moore JW, Robertson N, et al: Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res 61:7349-7355, 2001
96. Konishi T, Huang CL, Adachi M, et al: The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int J Oncol 16:501-511, 2000
97. Charvat S, Duchesne M, Parvaz P, et al: The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor. Anticancer Res 19:557-561, 1999
98. Ding I, Sun JZ, Fenton B, et al: Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res 61:526-531, 2001
99. Lord EM, Harwell L, Koch CJ: Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 53:5721-5726, 1993
100. Koch CJ, Evans SM, Lord EM: Oxygen dependence of cellular uptake of EF5 [2-(2-nitro, 1H-imidazol-1-yl)-N- (2,2,3,3,3-pentaluoropropyl)acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 72:869-874, 1995
101. Waleh NS, Brody MD, Knapp MA, et al: Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker. Cancer Res 55:6222-6226, 1995
102. Evans SM, Joiner B, Jenkins WT, et al: Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3- pentafluoropropyl) acetamide]. Br J Cancer 72:875-882, 1995
103. Ayene IS, Koch CJ, Krisch RE: Modification of radiation-induced strand breaks by glutathione: Comparison of single- and double-strand breaks in SV40 DNA. Radiat Res 144: 1-8, 1995
104. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000
105. Britten RA, Evans AJ, Allalunis-Turner MJ, et al: Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int J Radiat Oncol Biol Phys 34:367-374, 1996
106. Fenton BM, Paoni SF, Lee J, et al: Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements. Br J Cancer 79: 464-471, 1999
107. Lee J, Siemann DW, Koch CJ, et al: Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer 67: 372-378, 1996
108. Kavanagh MC, Tsang V, Chow S, et al: A comparison in individual murine tumors of techniques for measuring oxygen levels. Int J Radiat Oncol Biol Phys 44:1137-1146, 1999
109. Cohen-Jonathan E, Evans SM, Koch CJ, et al: The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61:2289-2293, 2001
110. Palcic B, Skarsgard LD: Reduced oxygen enhancement ratio at low doses of ionizing radiation. Radiat Res 100:328-339, 1984
111. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours [see comments]. Nature 379:88-91, 1996
112. Gatenby RA, Kessler HB, Rosenblum JS, et al: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988
113. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41:31-39, 1996
114. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
115. Hockel M, Knoop C, Schlenger K, et al: Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26:45-50, 1993
116. Hockel M, Schlenger K, Aral B, et al: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509-4515, 1996
117. Rofstad EK, Sundfor K, Lyng H, et al: Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 83:354-359, 2000
118. Fyles AW, Milosevic M, Wong R, et al: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48:149-156, 1998
119. Fyles A, Milosevic M, Hedley D, et al: Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20:680-687, 2002
120. Kallman RF: Reoxygenation and repopulation in irradiated tumors. Front Radiat Ther Oncol 22:30-49, 1988
121. Znati CA, Rosenstein M, Boucher Y, et al: Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res 56:964-968, 1996
122. Fenton BM, Paoni SF, Koch CJ, et al: Effect of local irradiation on tumor oxygenation, perfused vessel density, and development of hypoxia. Adv Exp Med Biol 454:619-628, 1998
123. Himelstein BP, Canete-Soler R, Bernhard EJ, et al: Metalloproteinases in tumor progression: The contribution of MMP-9. Invasion Metas 14:46-258, 1994
124. John A, Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7:14-23, 2001
125. Bernhard EJ, Muschel RJ, Hughes EN: Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 50:3872-3877, 1990
126. Bernhard EJ, Gruber SB, Muschel RJ: Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 91:4293-4297, 1994
127. Bernhard EJ, Hagner B, Wong C, et al: The effect of E1A transfection on MMP-9 expression and metastatic potential. Int J Cancer 60:718-724, 1995